Accessibility Menu
Immunocore Plc logo

Immunocore Plc(NASDAQ) IMCR

Market Cap$1.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-22%
5 Year+1%
1 Year-1%
1 Month+9%
$33.44
-0.21%
-0.07Today
Immunocore Plc last closing stock price
MetricPriceDate
Last closeUSD 33.512026-07-28
Immunocore Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.81%USD 34.482026-07-21
1 month+8.52%USD 30.882026-06-26
3 month+20.02%USD 27.922026-04-29
Year to date-3.46%USD 34.712025-12-31
1 year-1.27%USD 33.942025-07-28
3 year-49.06%USD 65.782023-07-28
5 year+0.93%USD 33.202021-07-29
Since inception-22.43%USD 43.202021-02-05

Immunocore Plc Financials at a Glance

Market Cap

$1.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$385.76M

Net Income (TTM)

-$18.82M

EPS (TTM)

-$0.52

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.78 (Low)

Price

$33.44

Volume

192,297.412

Open

$33.41

Previous Close

$33.42

Daily Range

$32.84 - $33.79

52-Week Range

$27.56 - $40.71

Estimated Earnings Date

Aug 6, 2026

IMCR News

Foolcom-Featured.png

Immunocore (IMCR) Q2 Revenue Jumps 30%

Motley Fool Markets TeamAug 7, 2025
GettyImages-506712124

What's Winning in 2022? 3 Stocks That Are Doing Fine

Taylor CarmichaelJul 16, 2022

IMCR: Motley Fool Moneyball Superscore

69

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immunocore Plc

Immunocore makes medicines that teach the immune system to find and kill diseased cells. These products help people with rare cancers and long-term viral infections. The company uses specialized protein technology to target parts of a cell that standard drugs often miss.

Medicines Built to Target Disease

  • KIMMTRAK: Approved medicine for a rare eye cancer that has spread to other body parts; accounts for 100% of revenue from therapy sales.
  • ImmTAC Platform: Cancer-fighting molecules that help T cells recognize and destroy tumor cells; used in three current late-stage clinical programs.
  • ImmTAV Platform: Treatments designed to help the immune system control or cure viral infections like HIV and Hepatitis B.
  • ImmTAAI Platform: Medicines for autoimmune diseases, such as Type 1 diabetes, that stop the immune system from attacking healthy tissue.

Growing Beyond a Single Drug

  • Signed a distribution agreement with Er-Kim Pharmaceuticals Bulgaria EOOD in 2025 to sell KIMMTRAK in the Middle East and North Africa.
  • Started a partnership with Bristol-Myers Squibb in February 2024 to test a new cancer treatment in a Phase 3 study.
  • Submitted a clinical trial application for its first autoimmune medicine, IMC-S118AI, in December 2025.
  • Collaborated with the Bill & Melinda Gates Foundation to develop a potential treatment for HIV.

Why the Technology is Different

Immunocore uses T cell receptors (TCRs) to target intracellular proteins, which make up 90% of all proteins in the body. This approach allows the company to reach disease targets that traditional antibody-based therapies cannot see.

Recent Financial Performance

  • Annual revenue reached $400 million in 2025, up 29% from $310 million in 2024.
  • Net loss reached $22.3 million in Q4 2025, an improvement of 6.3% from the $23.8 million loss in Q4 2024.
  • Free cash flow was negative $35.5 million in Q4 2025, which worsened by 102.7% compared to the previous year.
  • United States sales accounted for $257 million in 2025, representing roughly 64% of total therapy revenue.

Bottom Line

Immunocore has transitioned from a research firm into a commercial biotech company with global sales. It is now applying its unique protein technology to expand from cancer treatments into infectious and autoimmune diseases.

AI Generated • Apr 30, 2026

Industry

Biotechnology

Sector

Health Care

Employees

524

CEO

Bahija Jallal, PhD

Website

immunocore.com

Headquarters

Abingdon, OX OX14 4RY, GB

IMCR Financials

Key Financial Metrics (TTM)

Gross Margin

98.81%

Operating Margin

-7.61%

Net Income Margin

-4.88%

Return on Equity

-4.83%

Return on Capital

-4.13%

Return on Assets

-1.76%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.83M

Volume

192.30K

Avg. Volume

512.86K

Financials (TTM)

Gross Profit

$381.15M

Operating Income

-$29.36M

EBITDA

$6.24M

Operating Cash Flow

-$24.90M

Capital Expenditure

-$5.82M

Free Cash Flow

-$30.72M

Cash & ST Invst.

$844.90M

Total Debt

$435.68M

Immunocore Plc Performance Analysis

Immunocore Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 177,052,388385.4%
20232023-12-31USD 250,394,80141.4%
20242024-12-31USD 310,332,53023.9%
20252025-12-31USD 400,950,78629.2%
Immunocore Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.3%
Q32025-09-305.8%
Q42025-12-31-25.3%
Q12026-03-3137.8%
Immunocore Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-316.3%
Q32025-09-30107.4%
Q42025-12-31-2920.5%
Q12026-03-31156.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$106.68M

+13.6%

Gross Profit

$106.24M

+14.2%

Gross Margin

99.59%

N/A

Market Cap

$1.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.25M

N/A

Employees

524

N/A

Net Income

$12.97M

+158.2%

EBITDA

$16.53M

+65.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$844.90M

+0.9%

Total Debt

$435.68M

+0.4%

Accounts Receivable

$81.07M

+28.5%

Inventory

$8.25M

+21.3%

Long Term Debt

$433.69M

+0.3%

Short Term Debt

$2.00M

+16.2%

Return on Assets

-1.76%

N/A

Return on Invested Capital

-3.53%

N/A

Free Cash Flow

-$15.53M

-11435.7%

Operating Cash Flow

-$13.75M

-3261.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ABCLAbCellera Biologics Inc.
$5.39+1.89%
XERSXeris Biopharma Holdings, Inc.
$8.38+1.70%
BHVNBiohaven Ltd.
$13.43-2.47%
SIONSionna Therapeutics, Inc.
$44.81-3.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About IMCR

What is the current price of Immunocore Plc?

Immunocore Plc is trading at $33.42 per share.

What is the 52-week range for Immunocore Plc?

Over the past 52 weeks, Immunocore Plc has traded between $27.56 and $40.71.

How much debt does Immunocore Plc have?

As of the most recent reporting period, Immunocore Plc reported total debt of $435.68M.

How much cash does Immunocore Plc have on hand?

Immunocore Plc reported $452.68M in cash and cash equivalents in its most recent financial results.

What is Immunocore Plc’s dividend yield?

Immunocore Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services